CBD Market

CBD-brand MYO launches in Boots across the UK

MYO will be available in 838 Boots stores across the country.

CBD-brand MYO launches in Boots across the UK

CBD-brand MYO has hit a major milestone in its journey with a new partnership that will see its products stocked in the leading UK health and beauty retailer’s stores.

Boots will stock MYO‘s Plant Proteins in 838 stores, branched-chain amino acids and essential amino acids in up to 574 stores, and functional sprays in 522 stores.

MYO, acquired by global vertically integrated wellness platform Yooma Wellness in March 2021, is one of the few brands whose CBD products have passed the UK Food Standard Agency’s (FSA) validation assessment.

James Lawson Baker, Founder of MYO Plant Nutrition, commented: “This is a major milestone for MYO and we are absolutely delighted to be partnering with Boots, the leading health and beauty retailer in the UK.

“A listing of this size gives the brand enormous national exposure and deepens our footprint within mainstream UK retail.

Read more: Yooma: building a vertically integrated CBD and wellness platform

“The listing will support MYO in making plant-based active nutrition and wellness products mainstream and accessible.

“The partnership is a testament to the high-quality product and brand offering that we have built over the past year.  We look forward to building our credibility amongst Boots’ customers going forward.”

The product listing with Boots adds to its list of retail chains where its products are available, including Holland & Barrett, Selfridges, Lloyds Pharmacy and Amazon.

Jordan Greenberg, CEO of Yooma, commented: “MYO Plant Nutrition is an exceptional example of how Yooma’s buy-and-build strategy creates shareholder value.

“MYO continues to surpass expectations with its increased availability in UK’s most reputable retailers and it has the honour of being known as one of the few brands to have passed the FSA’s validation assessment.”

[activecampaign form=31]

Topicscannabis industryCBD industryCBD productsuk

Stephanie Price

Stephanie is a journalist for Business of Cannabis, writing about science, research, policy and industry developments in cannabis, CBD and psychedelics. In 2013 Stephanie gained her BA in English and Media, focusing on journalism and propaganda, where her magazine 'Game Theory' focused on developments and disruptors over the coming decade including cannabis, psychedelics, blockchain/crypto and free speech. In 2015 Stephanie received her National Council for the Training of Journalists (NCTJ) diploma whilst working as a reporter in North Wales. Stephanie has a specialism in Medical Cannabis: The Health Effects of THC and CBD through the University of Colorado, and a certificate from the Medical Cannabis Clinicians Society on "Medical Cannabis Explained".

More from Stephanie

Spotted an error, or have a tip? Contact the newsroom.

Up next · CBD Market

California’s Beard Bros Enters UK and European CBD Markets Through BRITISH CANNABIS Partnership

BusinessOfCannabis · 12 October 2026

More